KRAS-话题@MedSci

#KRAS#

77篇内容 | 4149人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1369043, encodeId=4dec136904338, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=AACR 2022：Sotorasib在KRAS G12C+ NSCLC的2年生存率上表现惊人, objectType=article, longId=724154, objectId=839ce2415432, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=839ce2415432, replyNumber=0, likeNumber=101, createdTime=2022-04-14, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=839ce2415432, moduleTitle=AACR 2022：Sotorasib在KRAS G12C+ NSCLC的2年生存率上表现惊人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=839ce2415432)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369042, encodeId=9b701369042c1, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响, objectType=article, longId=301463, objectId=dae03014634c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dae03014634c, replyNumber=0, likeNumber=126, createdTime=2022-03-24, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dae03014634c, moduleTitle=Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dae03014634c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369041, encodeId=f88c1369041a9, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=英国NICE推荐安进的Lumykras (sotorasib) 治疗非小细胞肺癌, objectType=article, longId=300150, objectId=17e0300150e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17e0300150e7, replyNumber=0, likeNumber=106, createdTime=2022-03-07, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17e0300150e7, moduleTitle=英国NICE推荐安进的Lumykras (sotorasib) 治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17e0300150e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369040, encodeId=2cba136904077, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=JAMA Surg: KRAS变异与手术切除的肝内胆管细胞癌(ICC)患者的生存和复发风险的关系, objectType=article, longId=220647, objectId=481022064e52, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=481022064e52, replyNumber=0, likeNumber=109, createdTime=2021-11-21, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=481022064e52, moduleTitle=JAMA Surg: KRAS变异与手术切除的肝内胆管细胞癌(ICC)患者的生存和复发风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=481022064e52)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369039, encodeId=fffe13690396c, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析, objectType=article, longId=218842, objectId=20e9218842d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e9218842d0, replyNumber=0, likeNumber=113, createdTime=2021-10-20, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e9218842d0, moduleTitle=Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20e9218842d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369038, encodeId=903e136903817, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=KRAS G12C突变癌症治疗新突破，KRAS抑制剂的新组合显示积极结果, objectType=article, longId=218574, objectId=67f02185e4be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67f02185e4be, replyNumber=0, likeNumber=107, createdTime=2021-10-16, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67f02185e4be, moduleTitle=KRAS G12C突变癌症治疗新突破，KRAS抑制剂的新组合显示积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67f02185e4be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369037, encodeId=f7cd136903ec7, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较, objectType=article, longId=218078, objectId=d5152180e802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5152180e802, replyNumber=0, likeNumber=120, createdTime=2021-10-05, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5152180e802, moduleTitle=Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5152180e802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369036, encodeId=ae23136903678, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=信达生物与劲方医药关于GFH925（KRAS G12C抑制剂）达成全球战略合作, objectType=article, longId=216609, objectId=cb44216609d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb44216609d0, replyNumber=0, likeNumber=179, createdTime=2021-09-04, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb44216609d0, moduleTitle=信达生物与劲方医药关于GFH925（KRAS G12C抑制剂）达成全球战略合作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb44216609d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369035, encodeId=2b87136903500, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Lung Cancer：KRAS G12C突变的晚期非小细胞肺癌治疗:来自德国前瞻性、观察性、全国性CRISP注册登记 (AIO-TRK-0315)的真实队列研究, objectType=article, longId=214247, objectId=743821424e04, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=743821424e04, replyNumber=0, likeNumber=88, createdTime=2021-07-16, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=743821424e04, moduleTitle=Lung Cancer：KRAS G12C突变的晚期非小细胞肺癌治疗:来自德国前瞻性、观察性、全国性CRISP注册登记 (AIO-TRK-0315)的真实队列研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=743821424e04)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369034, encodeId=03a41369034f8, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=NEJM：KRAS抑制剂获得性耐药机制研究, objectType=article, longId=213196, objectId=8eda2131962c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eda2131962c, replyNumber=0, likeNumber=104, createdTime=2021-06-26, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eda2131962c, moduleTitle=NEJM：KRAS抑制剂获得性耐药机制研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eda2131962c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369033, encodeId=177713690331e, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人, objectType=article, longId=212430, objectId=207d212430a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=207d212430a0, replyNumber=0, likeNumber=86, createdTime=2021-06-09, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=207d212430a0, moduleTitle=NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=207d212430a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369032, encodeId=c1501369032f5, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=KRAS抑制剂获美国FDA加速批准，治疗非小细胞肺癌, objectType=article, longId=212097, objectId=f6de21209e2c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6de21209e2c, replyNumber=0, likeNumber=86, createdTime=2021-06-02, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6de21209e2c, moduleTitle=KRAS抑制剂获美国FDA加速批准，治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6de21209e2c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369031, encodeId=071f13690314f, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=JTO: KRAS G12C突变在非小细胞肺癌（NSCLC）的预后价值研究：来自欧洲胸部肿瘤组肺癌数据库项目, objectType=article, longId=212016, objectId=e0a7212016a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0a7212016a2, replyNumber=0, likeNumber=86, createdTime=2021-05-31, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0a7212016a2, moduleTitle=JTO: KRAS G12C突变在非小细胞肺癌（NSCLC）的预后价值研究：来自欧洲胸部肿瘤组肺癌数据库项目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0a7212016a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369030, encodeId=7214136903072, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益, objectType=article, longId=206081, objectId=4595206081b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4595206081b2, replyNumber=0, likeNumber=0, createdTime=2021-01-24, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4595206081b2, moduleTitle=复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4595206081b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369029, encodeId=5680136902941, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比, objectType=article, longId=205368, objectId=7c3220536802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c3220536802, replyNumber=0, likeNumber=0, createdTime=2021-01-07, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c3220536802, moduleTitle=KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c3220536802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369028, encodeId=70d913690281c, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=安进公司向EMA提交KRAS抑制剂sotorasib治疗非小细胞肺癌的上市申请, objectType=article, longId=204984, objectId=f80e2049842c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f80e2049842c, replyNumber=0, likeNumber=68, createdTime=2020-12-31, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f80e2049842c, moduleTitle=安进公司向EMA提交KRAS抑制剂sotorasib治疗非小细胞肺癌的上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f80e2049842c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369027, encodeId=c14c136902e7c, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展, objectType=article, longId=202536, objectId=c48320253636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c48320253636, replyNumber=0, likeNumber=80, createdTime=2020-10-28, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c48320253636, moduleTitle=KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c48320253636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369026, encodeId=833d136902630, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=KRAS最快品种II期曙光初现，在肺癌领域显示出疗效, objectType=article, longId=201982, objectId=c13d20198295, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c13d20198295, replyNumber=0, likeNumber=80, createdTime=2020-10-13, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c13d20198295, moduleTitle=KRAS最快品种II期曙光初现，在肺癌领域显示出疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c13d20198295)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369025, encodeId=d9771369025ce, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=NEJM：Sotorasib治疗KRAS突变晚期实体瘤效果显著, objectType=article, longId=201173, objectId=98dc2011e3ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98dc2011e3ba, replyNumber=0, likeNumber=81, createdTime=2020-09-26, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98dc2011e3ba, moduleTitle=NEJM：Sotorasib治疗KRAS突变晚期实体瘤效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98dc2011e3ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1369024, encodeId=51d51369024db, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Br J Cancer：新一代抗体-药物偶联物有望治疗KRAS突变型胰腺癌, objectType=article, longId=200728, objectId=dc7f200e286c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc7f200e286c, replyNumber=0, likeNumber=76, createdTime=2020-09-17, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc7f200e286c, moduleTitle=Br J Cancer：新一代抗体-药物偶联物有望治疗KRAS突变型胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc7f200e286c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

KRAS

2020-05-29

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

AACR 2022：Sotorasib在KRAS G12C+ NSCLC的2年生存率上表现惊人

2022-04-14

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响

2022-03-24

heli0118 (审核中...)

前往app查看评论内容

#KRAS#

英国NICE推荐安进的Lumykras (sotorasib) 治疗非小细胞肺癌

2022-03-07

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

JAMA Surg: KRAS变异与手术切除的肝内胆管细胞癌(ICC)患者的生存和复发风险的关系

2021-11-21

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析

2021-10-20

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

KRAS G12C突变癌症治疗新突破，KRAS抑制剂的新组合显示积极结果

2021-10-16

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较

2021-10-05

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

信达生物与劲方医药关于GFH925（KRAS G12C抑制剂）达成全球战略合作

2021-09-04

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

Lung Cancer：KRAS G12C突变的晚期非小细胞肺癌治疗:来自德国前瞻性、观察性、全国性CRISP注册登记 (AIO-TRK-0315)的真实队列研究

2021-07-16

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

NEJM：KRAS抑制剂获得性耐药机制研究

2021-06-26

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人

2021-06-09

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

KRAS抑制剂获美国FDA加速批准，治疗非小细胞肺癌

2021-06-02

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

JTO: KRAS G12C突变在非小细胞肺癌（NSCLC）的预后价值研究：来自欧洲胸部肿瘤组肺癌数据库项目

2021-05-31

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益

2021-01-24

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比

2021-01-07

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

安进公司向EMA提交KRAS抑制剂sotorasib治疗非小细胞肺癌的上市申请

2020-12-31

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展

2020-10-28

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

KRAS最快品种II期曙光初现，在肺癌领域显示出疗效

2020-10-13

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

NEJM：Sotorasib治疗KRAS突变晚期实体瘤效果显著

2020-09-26

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

Br J Cancer：新一代抗体-药物偶联物有望治疗KRAS突变型胰腺癌

2020-09-17

科室
- - 订阅+
  - 更多科室
工具
服务